Premenstrual syndrome/premenstrual dysphoric disorder

Clinical Gynecology

Volumn , Issue , 2006, Pages 19-35

  Brown, Candace ^a   Ling, Frank W ^b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Women's Health Specialists PLLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 53649102980     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06691-7.50007-8     Document Type: Chapter

References (136)

1. American College of Obstetricians and Gynecologists: Premenstrual Syndrome. ACOG Practice Bulletin No. 15, Apr 2000. (IV, C).
2. Freeman EW Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs 2004, 18:453-468. (IV, C).
3. Johnson SR Premenstrual syndrome. Textbook of Women's Health 1998, 691-697. Lippincott-Raven, Philadelphia, (IV, C). L.A. Wallis (Ed.).
4. Robinson GE, Stewart DF Psychological aspects of premenstrual syndrome. Textbook of Women's Health 1998, 699-701. Lippincott-Raven, Philadelphia, (IV, C). L.A. Wallis (Ed.).
5. Dalton K The premenstrual syndrome and progesterone therapy 1984, Year Book, Chicago, (IV, C). 2nd ed.
6. Steiner M, Pearlstein T Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000, 61(Suppl 12):17-21. (IV, C).
7. Rapkin AJ, Edelmuth E, Chang LC, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987, 70:533-537. (Ib, A).
8. Taylor DL, Mathew RJ, Ho BT, et al. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984, 12:16-18. (Ib, A).
9. Rasgon N, Serra M, Biggio G, et al. Neuroactive steroid-serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Eur J Endocrinol 2001, 145:25-33. (IIa, B).
10. FitzGerald M, Malone KM, Li S, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. Am J Psychiatry 1997, 154:556-558. (Ib, A).
11. Yatham LN Is 5HT 1α receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study. Can J Psychiatry 1993, 38:662-664. (IIa, B).
12. Mitwally MF, Kahn LS, Halbreich U Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: current practices. Expert Opin Pharmacother 2002, 3:1577-1590. (IV, C).
13. Roca CA, Schmidt PJ, Bloch M, et al. Implications of endocrine studies of premenstrual syndrome. Psychiatr Ann 1996, 26:576-580. (IV, C).
14. Ross LE, Steiner M A biopsychosocial approach to premenstrual dysphoric disorder. Psychiatr Clin North Am 2003, 26:529-546. (IV, C).
15. Rapkin AJ A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology 2003, 28(Suppl 3):39-53. (IV, C).
16. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997, 90:709-714. (IIa, B).
17. Freeman EW, Frye CA, Rickels K, et al. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. J Clin Psychopharmacol 2002, 22:516-520. (IIa, B).
18. Le Melledo JM, Van Driel M, Coupland NK, et al. Response to flumazenil in women with premenstrual dysphoric disorder. Am J Psychiatry 2000, 157:821-823. (Ib, A).
19. Sundstrom I, Nyberg S, Backstrom T Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology 1997, 17:370-381. (Ib, A).
20. Eriksson E, Sundblad C, Landen M, et al. Behavioral effects of androgens in women. Mood Disorders in Women 2000, 233-246. Martin Dunitz, London, (IV, C). M. Steiner, K.A. Yonkers, E. Ericksson (Eds.).
21. Steiner M, Dunn EJ, MacDougall M, et al. Serotonin transporter gene polymorphism, free testosterone, and symptoms associated with premenstrual dysphoric disorder. Biol Psychiatry 2002, 51:91S. (IIa, B).
22. Condon JT The premenstrual syndrome: a twin study. Br J Psychiatry 1993, 162:481-486. (IV, C).
23. Kendler KS, Karkowski LM, Corey LA, et al. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. Am J Psychiatry 1998, 155:1234-1240. (IIa, B).
24. Halbreich U, Bergeron R, Yonkers KA, et al: Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Poster presented at the 39th annual meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico, Dec 10-14, 2000. (Ib).
25. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, text revision (IV, C). 4th ed.
26. Hart WG, Coleman GJ, Russell JW Assessment of premenstrual symptomatology: a re-evaluation of the predictive validity of self-report. J Psychosom Res 1987, 31:185-190. (III).
27. Thys-Jacobs A, Fratarcangelo P Comparative analysis of three PMS assessment instruments-the identification of premenstrual syndrome with core symptoms. Psychopharmacol Bull 1995, 31:389-396. (IIa, B).
28. Endicott J Severe premenstrual dysphoria: differential diagnosis and treatment. J Am Med Womens Assoc 1998, 53:170-175. (IV, C).
29. Smith MJ, Schmidt PJ, Rubinow DR Operationalizing DSM-IV criteria for PMDD: selecting symptomatic an asymptomatic cycles for research. J Psychiatr Res 2003, 37:75-83. (IV, C).
30. Endicott J The menstrual cycle and mood disorders. J Affect Disord 1993, 29:193-200. (IV, C).
31. Freeman EW, Sondheimer SJ Premenstrual dysphoric disorder: recognition and treatment. J Clin Psychiatry 2003, 5:30-39. (IV, C).
32. Frackiewicz EJ, Shiovitz TM Evaluation and management of premenstrual syndrome and premenstrual dysphoric disorder. J Am Pharm Assoc 2001, 41:437-447. (IV, C).
33. Steege JF, Blumenthal JA The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study. J Psychosom Res 1993, 37:127-133. (Ib, A).
34. Prior JC, Vigna Y, Sciarretta DS, et al. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. Fertil Steril 1987, 47:402-408. (IIa, B).
35. Sundstrom I, Backstrom T Patients with premenstrual syndrome have decreased saccadic eye velocity compared to control subjects. Biol Psychiatry 1998, 44:755-764. (Ib, A).
36. Morse G Positively reframing perceptions of the menstrual cycle among women with premenstrual syndrome. J Obstet Gynecol Neonatal Nurs 1999, 28:165-174. (IIa, B).
37. Taylor D Effectiveness of professional-peer group treatment: symptom management for women with PMS. Res Nurs Health 1999, 22:496-511. (IIa, B).
38. Blake F, Salkovskis P, Gath D, et al. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998, 45:307-318. (Ib, A).
39. Morse CA, Dennerstein L, Farrell E, et al. A comparison of hormone therapy, coping skills training, and relaxation for the relief of premenstrual syndrome. Behav Med 1991, 14:469-489. (Ib, A).
40. Kirkby RJ Changes in premenstrual symptoms and irrational thinking following cognitive-behavioral coping skills training. J Consult Clin Psychol 1994, 62:1026-1032. (Ib, A).
41. Hunter MS, Ussher JM, Browne SJ, et al. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002, 23:193-199. (Ib, A).
42. Hunter MS, Ussher JM, Cariss M, et al. Medical (fluoxetine) and psychological (cognitive-behavioral therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes. J Psychosom Res 2002, 53:811-817. (Ib, A).
43. Thys-Jacobs P, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998, 179:444-452. (Ib, A).
44. Blumenthal M, Busse WR, Goldberg A, et al. The complete German Commission E monographs: therapeutic guide to herbal medicines 1998, 1694. American Botanical Council, Austin, Tex, (IV, C).
45. Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998, 7:1157-1165. (IIb, B).
46. Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991, 78:177-181. (IIb, B).
47. Girman A, Lee R, Kligler B An integrative medicine approach to premenstrual syndrome (editorial). Am J Obstet Gynecol 2003, 188(Suppl 5):S56-S65. pt 2 (IV, C).
48. London BS, Murphy L, Kitlowski KE, et al. Efficacy of alpha-tocopherol in the treatment of the premenstrual syndrome. J Reprod Med 1987, 32:400-404. (Ib, A).
49. Wyatt RM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999, 318:1375-1381. (Ia, A).
50. Dittmar G, Bohnert K Premenstrual syndrome: treatment with phytopharmaceutical. TW Gynakol 1992, 5:60-68. (Ib, A).
51. Schellenberg R Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomized, placebo-controlled study. BMJ 2001, 322:134-137. (Ib, A).
52. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000, 132:743-756. (IV, C).
53. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St. John's wort in major depression: a randomized placebo controlled trial. JAMA 2001, 285:1978-1986. (Ib, A).
54. Stevinson C, Ernst E A pilot study of hypericum perforatum for the treatment of premenstrual syndrome. BJOG 2000, 107:870-876. (IIb, B).
55. Horribin DF, Manku MS, Brush M, et al. Abnormalities in plasma essential fatty acid levels in women with premenstrual syndrome and nonmalignant breast disease. J Nutr Med 1991, 2:259-264. (IIa, B).
56. Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000, 356:1131-1136. (Ia, A).
57. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995, 332:1529-1534. (Ib, A).
58. Wood SH, Mortola JF, Chan YF, et al. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. Obstet Gynecol 1992, 80:339-344. (Ib, A).
59. Ozeren S, Corakci A, Yucesoy I, et al. Fluoxetine in the treatment of premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 1997, 73:167-170. (Ib, A).
60. Pearlstein TB, Stone AB, Lund S Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997, 17:261-266. (Ib, A).
61. Su TP, Schmidt PJ, Danaceau MA, et al. Fluoxetine in the treatment of premenstrual dysphoria. Neuropsychopharmacology 1997, 16:346-356. (Ib, A).
62. Stone AB, Pearlstein TB, Brown WA Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1991, 52:290-293. (Ib, A).
63. Menkes DB, Taghavi E, Mason PA, et al. Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol 1993, 8:95-102. (Ib, A).
64. Cohen LS, Miner C, Brown E, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled clinical trial using computerized diaries. Obstet Gynecol 2002, 100:435-444. (Ib, A).
65. Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002, 24:417-433. (Ib, A).
66. Steiner M, Korzekwa M, Lamont J, et al. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997, 33:771-774. (III, B).
67. Pearlstein T, Yonkers K Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder. Expert Opin Pharmacother 2002, 3:979-991. (IV, C).
68. Halbreich U, Smoller JW Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 1997, 58:399-402. (III, B).
69. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999, 8:328-332. (Ib, A).
70. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998, 59:76-80. (Ib, A).
71. Freeman EW, Rickels K, Arredondo F, et al. Full-or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999, 19:3-8. (III, B).
72. Freeman EW, Rickels K, Sondheimer SJ, et al. Continuous or intermittent dosing with sertraline for severe premenstrual syndrome/premenstrual dysphoric disorder. Am J Psychiatry 2004, 161:343-351. (III, B).
73. Halbreich M, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002, 100:1219-1229. (Ib, A).
74. Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release is effective in treating premenstrual dysphoric disorder [abstract]. Obstet Gynecol 2003, 101(Suppl 4):111S. (Ib, A).
75. Gee M, Bellew KM, Holland FJ, et al: Luteal phase dosing of paroxetine controlled release is effective in treating PMDD [abstract No. NR760 plus poster]. American Psychiatric Association 2003 annual meeting. San Francisco, May 17-22, 2003. (Ib, A).
76. Eriksson E, Hedberg A, Andersch B, Sunblad C The SSRI paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacol 1995, 12:167-176. (Ib, A).
77. Yonkers KA, Gullion C, Williams A, et al. Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol 1996, 16:3-8. (Ib, A).
78. Wikander I, Sundblad C, Andersch B, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phase more effective than continuous medication throughout the menstrual cycle?. J Clin Psychopharmacol 1998, 18:390-398. (Ib, A).
79. Sundblad C, Wikander I, Andersch B, et al. A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side effects during ten cycles of treatment. Eur Neuropsychopharmacol 1997, 7:201-206. (III, B).
80. Freeman EW, Jabara S, Sondheimer SF, et al. Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study. J Womens Health Gend Based Med 2002, 11:459-464. (III, B).
81. Freeman EW, Rickels K, Sondheimer SJ Fluvoxamine for premenstrual dysphoric disorder: a pilot study. J Clin Psychiatry 1996, 57(Suppl 8):56-60. (IIb, B).
82. Veeninga AT, Westenberg HG, Weusten JT Fluvoxamine in the treatment of premenstrually related mood disorders. Psychopharmacology (Berl) 1990, 102:414-416. (Ib, A).
83. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997, 278:983-988. (Ib, A).
84. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol 2001, 98:737-744. (Ib, A).
85. Wells BG, Mandos LA, Hayes PE Depressive disorders. Pharmacotherapy: A Pathophysiologic Approach 1999, 1141-1160. Appleton & Lange, Stamford, Conn, (IV, C). J.T. Dipiro, R.L. Talbert, G.C. Yee (Eds.).
86. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002, 63:357-366. (IV, C).
87. Landen M, Eriksson O, Sundblad C, et al. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl) 2001, 155:292-298. (Ib, A).
88. Rothschild AJ Sexual side effects of antidepressants. J Clin Psychiatry 2000, 61:28-36. (IV, C).
89. Eriksson E Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. Int Clin Psychopharmacol 1999, 14(Suppl 2):S27-S33. (IV, C).
90. Pearlstein T, Gillespie JA: When should premenstrual dosing in PMDD end? Poster presentation, 155th Annual APA American Psychiatric Association meeting. Philadelphia, 2002. (III, B).
91. Goldstein BJ, Goodnick PJ Selective serotonin reuptake inhibitors in the treatment of affective disorders. 3. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998, 12(3 Suppl B):S55-S87. (IV, C).
92. Freeman EW, Sondheimer SJ, Rickels K, et al. A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndrome. J Clin Psychopharmacol 2004, 24:1-2. (III, B).
93. Pearlstein TB, Stone AB Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994, 55:332-335. (IIb, B).
94. Yonkers KA, Barnett LK, Carmody T, et al. Serial discontinuation of SSRI treatment for PMDD. Biol Psychol 1998, 43(Suppl 8):358. (IIb, B).
95. Kulin NA, Pastuszak A, Sager S, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998, 279:609-610. (IIa, B).
96. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in vitro to antidepressant drugs. N Engl J Med 1997, 336:258-262. (IIa, B).
97. Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001, 179:163-166. (III, B).
98. Harvey AT, Preskorn SH Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Pt 1. J Clin Psychopharmacol 1996, 6:273-285. (IV, C).
99. Harvey AT, Preskorn SH Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Pt 11. J Clin Psychopharmacol 1996, 16:345-355. (IV, C).
100. Kornstein S, Pearlstein T, Farfel G, et al: Efficacy of sertraline in the treatment of premenstrual syndrome. Poster presented at the 41st annual meeting of the New Clinical Drug Evaluation Unit. Phoenix, Ariz, May 28-31, 2001. (Ib, A).
101. Freeman EW, Sondheimer SJ, Rickels K, et al: A pilot study of extended sertraline treatment for severe PMS. Poster presented at the 155th annual meeting of the American Psychiatric Association. Philadelphia, May 18-23, 2002. (IIb, B).
102. Rickels K, Freeman E, Sondheimer S Buspirone in treatment of premenstrual syndrome [letter]. Lancet 1989, 1:777. (Ib, A).
103. Sundblad C, Hedberg M, Eriksson E Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. Neuropsychopharmacology 1993, 9:133-145. (Ib, A).
104. Graham CA, Sherwin BB A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. Psychosom Res 1992, 36:257-266. (Ib, A).
105. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, et al. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception 1992, 36:257-266. (III, B).
106. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996, 54:243-251. (IV, C).
107. Parsey KS, Pong A An open-label multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 2000, 61:105-111. (III, B).
108. Sulak PJ, Scow RD, Preece D, et al. Hormone withdrawal symptoms in oral contraceptive users, continuous use. Obstet Gynecol 2000, 95:261-266. (IV, C).
109. Watson NR, Studd JWW, Savvas M, et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989, 2:730-732. (III, B).
110. Freeman E, Rickels K, Sondheimer SJ, et al. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA 1990, 264:349-353. (Ib, A).
111. Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995, 274:51-57. (Ib, A).
112. Wyatt K, Dimmock P, Jones P, et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001, 323:776-780. (Ia, A).
113. O'Brien PMS, Abukhalil I Randomized controlled trial of the management of premenstrual mastalgia using luteal phase only Danazol. Am J Obstet Gynecol 1999, 180:18-23. (Ib, A).
114. Freeman EW, Sondheimer SJ, Rickels K Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997, 33:303-309. (Ib, A).
115. Johnson SR Premenstrual syndrome therapy. Clin Obstet Gynecol 1998, 41:405-421. (IV, C).
116. West CP, Hillier H Ovarian suppression with the gonadotropin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reprod 1994, 9:1058-1063. (Ib, A).
117. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998, 338:209-216. (Ib, A).
118. Mortola AJF, Girton L, Fischer U A successful treatment of severe premenstrual syndrome by combined use of gonadotropin-releasing hormone agonist and estrogen/progestin. J Clin Endocrinol Metab 1991, 72:252A. 252F, (Ib, A).
119. Casper RF, Heart MT The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am J Obstet Gynecol 1990, 162:105-109. (IIb, B).
120. Casson P, Hahn PM, Van Vugt DA, et al. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am J Obstet Gynecol 1990, 162:99-105. (IIb, B).
121. Berger CP, Presser B Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994, 84:379-385. (Ib, A).
122. Harrison WM, Endicott J, Nee J Treatment of premenstrual dysphoria with alprazolam: a controlled study. Arch Gen Psychiatry 1990, 47:270-275. (Ib, A).
123. Smith S, Rinehart JS, Ruddock VE, et al. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 1987, 70:37-43. (Ib, A).
124. Schmidt PJ, Grover GN, Rubinow DR Alprazolam in the treatment of premenstrual syndrome: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1993, 50:467-473. (Ib, A).
125. Rickels K, Freeman EW Prior benzodiazepine exposure and benzodiazepine treatment outcome. J Clin Psychiatry 2000, 61:409-413. (IIb, B).
126. Gunston KD Premenstrual syndrome in Cape Town. 2. A double-blind placebo-controlled study of the efficacy of mefenamic acid. S Afr Med J 1986, 70:159-160. (Ib, A).
127. Jakubowicz DL, Godard E, Dewhurst J The treatment of premenstrual tension with mefenamic acid: analysis of prostaglandin concentrations. Br J Obstet Gynaecol 1984, 91:78-84. (IIa, B).
128. Rees MCP, Randle J, Yudkin P Mefenamic acid and the premenstrual syndrome. J Obstet Gynaecol 1991, 11:359-360. (IIa, B).
129. Wood C, Jakubowicz D The treatment of premenstrual symptoms with mefenamic acid. Br J Obstet Gynaecol 1980, 87:627-630. (IIa, B).
130. Mira M, McNeil D, Fraser IS, et al. Mefenamic acid in the treatment of premenstrual syndrome. Obstet Gynecol 1986, 68:395-398. (IIa, B).
131. Facchinetti F, Fioroni L, Sances G, et al. Naproxen sodium in the treatment of premenstrual symptoms: a placebo-controlled study. Gynecol Obstet Invest 1989, 28:205-208. (Ib, A).
132. Burnet RB, Radden HS, Easterbrook EG, et al. Premenstrual syndrome and spironolactone. Aust N Z J Obstet Gynaecol 1991, 31:366-368. (Ib, A).
133. Hellberg D, Claesson B, Nilsson S Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate. Int J Gynaecol Obstet 1991, 34:243-248. (Ib, A).
134. O'Brien PM, Craven D, Selby C, et al. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol 1979, 86:142-147. (Ib, A).
135. Vellacott ID, Schroff NE, Pearce MH, et al. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. Curr Med Res Opin 1987, 10:450-456. (Ib, A).
136. Wang M, Hammarback S, Lindhe BA, et al. Treatment of premenstrual syndrome by spironolactone: a double-blind placebo controlled study. Acta Obstet Gynecol Scand 1995, 74:803-808. (Ib, A).